{"id":"infliximab-infusion-aza-placebo-caps","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Infusion reactions"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Musculoskeletal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Infliximab is a chimeric monoclonal antibody that targets tumor necrosis factor-alpha (TNF-alpha), a cytokine involved in systemic inflammation. By binding to TNF-alpha, infliximab prevents the interaction between TNF-alpha and its receptors on the surface of immune cells, thereby inhibiting the inflammatory response. This mechanism of action is thought to contribute to the therapeutic effects of infliximab in treating various inflammatory conditions.","oneSentence":"Infliximab is a chimeric monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-alpha), preventing its interaction with cell surface TNF receptors and thereby inhibiting the inflammatory response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:04.259Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"}]},"trialDetails":[{"nctId":"NCT00094458","phase":"PHASE3","title":"Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC","status":"COMPLETED","sponsor":"Centocor Ortho Biotech Services, L.L.C.","startDate":"2005-03","conditions":"Crohn Disease","enrollment":508}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"infliximab infusion; AZA placebo caps","genericName":"infliximab infusion; AZA placebo caps","companyName":"Centocor Ortho Biotech Services, L.L.C.","companyId":"centocor-ortho-biotech-services-l-l-c","modality":"Biologic","firstApprovalDate":"","aiSummary":"Infliximab is a chimeric monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-alpha), preventing its interaction with cell surface TNF receptors and thereby inhibiting the inflammatory response. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}